EndometriosisEUmetriosisNCT07000786
EUmetriosis: Insights Into the Pathogenesis of Endometriosis
A study testing Endometrial biopsy or menstrual cup and blood sample in people with Endometriosis, run by Université Catholique de Louvain at 1 site in Belgium.
Trial summary
This study investigates epigenetic changes in menstrual effluent and plasma from women with endometriosis to identify potential non-invasive diagnostic biomarkers for the disease. Read more about this study
- Who is it for?
- Ages 18 to 56 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Endometriosis
- What is being tested?
- Endometrial biopsy or menstrual cup and blood sample
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteBelgium
- Study dates
- 12 May 2025to 31 Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 56 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Premenopausal
- In spontaneous menstrual cycle (no hormonal treatments for the last 3 months)
- Healthy or with a clear diagnosis of endometriosis via ultrasound, MRI or laparoscopy
Who cannot join
- HIV or Hepatitis positive
- Pregnancy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site, 1 recruiting
- Recruiting
Cliniques universitaires Saint-Luc
Brussels, 1200
Marie-Madeleine Dolmans, MD, PhD, +32 (0)2 764 5287, marie-madeleine.dolmans@uclouvain.be
Marie-Madeleine Dolmans, MD, PhD
About this study
This study investigates epigenetic changes in menstrual effluent and plasma from women with endometriosis to identify potential non-invasive diagnostic biomarkers for the disease.
- Conditions
- Endometriosis
- Being tested
- Endometrial biopsy or menstrual cup and blood sample
- Medical subject headings
- Endometriosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Endometrial biopsy or menstrual cup and blood sampleProcedure or surgery
Enrolled patients will give their menstrual effluent either via a menstrual cup or via a pipelle biopsy. They will also undergo a blood draw.
| Study group | Role | What they receive |
|---|---|---|
| Epigenetics characterization | Experimental | Not described Receives: Procedure: Endometrial biopsy or menstrual cup and blood sample |
What is being measured
The primary outcome is the main question the study is designed to answer.
Epigenetic analysis
Histone post-translational modifications
Measured: Throughout the entire study, approximately during 3,5 years
Epigenetic analysis
miRNA
Measured: Throughout the entire study, approximately during 3,5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2025
- Study start12 May 2025
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EndometriosisStudies of the same condition, open and under way.
- More trials run by Université Catholique de LouvainThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université Catholique de Louvain
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07000786
- Sponsor's protocol ID
- EUmetriosis
- Acronym
- EUmetriosis
- Status last verified
- Jun 2025
- First submitted
- 12 May 2025
- Last updated
- 3 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- EUmetriosis: Insights Into the Pathogenesis of Endometriosis
- ClinicalTrials.gov ID
- NCT07000786
- Acronym / sponsor ID
- EUmetriosis / EUmetriosis
- Conditions
- Endometriosis
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Université Catholique de LouvainUniversity, hospital or other
- Study start
- 12 May 2025 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 3 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study investigates epigenetic changes in menstrual effluent and plasma from women with endometriosis to identify potential non-invasive diagnostic biomarkers for the disease.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Epigenetics characterization | Experimental | Procedure: Endometrial biopsy or menstrual cup and blood sample |
Who may qualify
- Ages
- 18 to 56 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Premenopausal
- In spontaneous menstrual cycle (no hormonal treatments for the last 3 months)
- Healthy or with a clear diagnosis of endometriosis via ultrasound, MRI or laparoscopy
Key exclusion criteria (2 listed)
- HIV or Hepatitis positive
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Endometrial biopsy or menstrual cup and blood sampleEnrolled patients will give their menstrual effluent either via a menstrual cup or via a pipelle biopsy. They will also undergo a blood draw. | Procedure or surgery | Epigenetics characterization |
Primary outcome
Epigenetic analysis
Time frame: Throughout the entire study, approximately during 3,5 years
Histone post-translational modifications
Epigenetic analysis
Time frame: Throughout the entire study, approximately during 3,5 years
miRNA
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for Endometriosis
Not yet recruiting
Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in Women With Endometriosis
SIBO, Endometriosis
Recruiting
Endometriosis Transcriptomic Cell Atlas
Endometriosis, Infertility
Not yet recruiting
Psychotherapy in Patients With Endometriosis: Cognitive Behavioral Therapy Versus Acceptance and Commitment Therapy
Endometriosis, Adenomyosis
Not yet recruitingObservational study
Impact of a Diagnosis or Lack of a Diagnosis of Endometriosis Via a Saliva Test on Pain Catastrophizing, Quality of Life, Symptoms of Anxiety and Depression, and Treatment Adherence
Endometriosis
Not yet recruitingPhase 2
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
Endometriosis Pelvic, Endometriosis Ovaries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Endometrial biopsy or menstrual cup and blood sample in people with Endometriosis, run by Université Catholique de Louvain at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marie-Madeleine Dolmans, MD, PhD (+32 (0)2 764 5287, marie-madeleine.dolmans@uclouvain.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Epigenetic analysis (time frame: Throughout the entire study, approximately during 3,5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2025.